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Five-Year Clinical and Functional Multislice
Computed Tomography Angiographic Results
After Coronary Implantation of the Fully
Resorbable Polymeric Everolimus-Eluting Scaffold
in Patients With De Novo Coronary Artery Disease
The ABSORB Cohort A Trial
Yoshinobu Onuma, MD,* Dariusz Dudek, MD,y Leif Thuesen, MD,z
MarkWebster,MBCHB,zKoenNieman,MD, PHD,*xHectorM.Garcia-Garcia,MD, PHD,k
John A. Ormiston, MB CHB,{ Patrick W. Serruys, MD, PHD*
Rotterdam, the Netherlands; Krakow, Poland; Skejby, Denmark; and Auckland, New ZealandObjectives This study sought to demonstrate the 5-year clinical and functional multislice computed
tomography angiographic results after implantation of the fully resorbable everolimus-eluting scaffold
(Absorb BVS, Abbott Vascular, Santa Clara, California).
Background Multimodality imaging of the ﬁrst-in-humans trial using a ABSORB BVS scaffold
demonstrated at 2 years the bioresorption of the device while preventing restenosis. However, the
long-term safety and efﬁcacy of this therapy remain to be documented.
Methods In the ABSORB cohort A trial (ABSORB Clinical Investigation, Cohort A [ABSORB A]
Everolimus-Eluting Coronary Stent System Clinical Investigation), 30 patients with a single de novo
coronary artery lesion were treated with the fully resorbable everolimus-eluting Absorb scaffold at
4 centers. As an optional investigation in 3 of the 4 centers, the patients underwent multislice
computed tomography (MSCT) angiography at 18 months and 5 years. Acquired MSCT data were
analyzed at an independent core laboratory (Cardialysis, Rotterdam, the Netherlands) for quantitative
analysis of lumen dimensions and was further processed for calculation of fractional ﬂow reserve (FFR)
at another independent core laboratory (Heart Flow, Redwood City, California).
Results Five-year clinical follow-up is available for 29 patients. One patient withdrew consent after
6 months, but the vital status of this patient remains available. At 46 days, 1 patient experienced a single
episode of chest pain and underwent a target lesion revascularizationwith a slight troponin increase after
the procedure. At 5 years, the ischemia-driven major adverse cardiac event rate of 3.4% remained
unchanged. Clopidogrel was discontinued in all but 1 patient. Scaffold thrombosis was not observed in
any patient. Two noncardiac deaths were reported, 1 caused by duodenal perforation and the other from
Hodgkin’s disease. At 5 years, 18 patients underwent MSCT angiography. All scaffolds were patent, with
amedianminimal lumenarea of 3.25mm2 (interquartile range: 2.20 to 4.30). Noninvasive FFR analysiswas
feasible in 13 of 18 scans, which yielded a median distal FFR of 0.86 (interquartile range: 0.82 to 0.94).
Conclusions The low event rate at 5 years suggests sustained safety after the implantation of a fully
bioresorbable Absorb everolimus-eluting scaffold. Noninvasive assessment of the coronary artery with
an option of functional assessment could be an alternative to invasive imaging after treatment of
coronary narrowing with such a polymeric bioresorbable scaffold. (ABSORB Clinical Investigation,
Cohort A [ABSORB A] Everolimus-Eluting Coronary Stent System Clinical Investigation [ABSORB];
NCT00300131) (J Am Coll Cardiol Intv 2013;6:999–1009) ª 2013 by the American College of
Cardiology Foundation
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1000As an alternative approach to a metal drug-eluting stent,
a fully bioresorbable polymeric drug-eluting device may
scaffold the vessel after dilation to prevent acute closure and
late constrictive remodeling, but dissolve over time to restore
the native integrity of the coronary artery. Such a scaffold
does not preclude surgical revascularization, and enables
expansive remodeling, restores vasomotion, and is compat-
ible with the noninvasive imaging of coronary arteries with
either multislice computed tomography (MSCT) or
magnetic resonance imaging (1,2).
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Abbreviations
and Acronyms
CT = computed tomography
FFR = fractional ﬂow reserve
FFRCT = noninvasive
fractional ﬂow reserve
according to multislice
computed tomography
ID = ischemia-driven
IQR = interquartile range
IVUS = intravascular
ultrasound
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MSCT = multislice computed
tomography
OCT = optical coherence
tomography
PLLA = poly-L-lactide
PDLLA = poly-D,L-lactide
QCA = quantitative coronary
angiography
TLR = target lesion
revascularization
TVR = target vessel
revascularizationThe fully resorbable ever-
olimus-eluting Absorb scaffold
(Abbott Vascular, Santa Clara,
California) was tested in the ﬁrst-
in-humansABSORB (ABSORB
Clinical Investigation, Cohort
A [ABSORB A] Everolimus
Eluting Coronary Stent System
Clinical Investigation) trial
enrolling 30 patients with a single
de novo coronary artery lesion.
Two-year imaging follow-up of
the trial with multiple modality
imaging can be summarized as
follows (3,4): 1) bioresorption
of polymeric struts (documented
with intravascular ultrasonography
[IVUS] and optical coherence
tomography [OCT]); 2) late
enlargement of the lumen from
6 months to 2 years with plaque
reduction (IVUS and OCT); 3)
restoration of vasomotion and
endothelial function in some
patients; 4) restoration of physio-
logical cyclic (systolic anddiastolic)
strains; and 5) feasibility of
noninvasive imaging with MSCTat 18 months (4–7). However, the long-term outcomes of
biodegradation of the Absorb scaffold in human coronary
arteries as well as plaque and lumen evolution beyond 2 years
remains to be investigated to conﬁrm the safety and effective-
ness of the technology.
With the rapid technological advancement, cardiac
MSCT angiography is currently considered an established, Thoraxcenter, Erasmus Medical Center, Rot-
University, Krakow, Poland; zSkejby Sygehus,
enmark; xDepartment of Radiology, Thorax-
terdam, the Netherlands; kCardialysis, Rotter-
kland City Hospital, Auckland, New Zealand.technique for noninvasive evaluation of the coronary lumen
as well as coronary plaques (8). However, MSCT assessment
of the previously stented coronary artery is limited due to
metal artifacts. Because of its radiolucent, polylactide back-
bone, the Absorb scaffold does not affect computed
tomography (CT) image interpretation, and MSCT could
be used to assess changes in the lumen and vessels after
Absorb implantation. Furthermore, noninvasive fractional
ﬂow reserve (FFR) derived from MSCT was recently shown
to be feasible with high diagnostic performance for the
detection and exclusion of ﬂow-limiting coronary lesions
that cause ischemia, which might further reﬁne the quality of
the noninvasive follow-up (9).
We hereby report the 5-year clinical results, the luminal
measurement, and noninvasive FFR assessment by MSCT
in the original cohort of patients treated with an Absorb
scaffold in the ABSORB Cohort A trial.Methods
Study design. The design of this study was previously re-
ported (3). Brieﬂy, in this single-arm, prospective, open-
label study, with safety and imaging endpoints, 30 patients
were enrolled at 4 participating sites between March and
July 2006. Patients were older than 18 years of age with
a diagnosis of stable, unstable, or silent ischemia. All treated
lesions were single, de novo in a native coronary artery of
3.0 mm, <8 mm for the 12-mm scaffold or 14 mm for the
18-mm scaffold (only 2 patients received an 18-mm scaf-
fold), with a percentage of diameter stenosis 50% and
<100% with a Thrombolysis In Myocardial Infarction ﬂow
grade of 1. Major exclusion criteria were patients pre-
senting with an acute myocardial infarction (MI), unstable
arrhythmias, or a left ventricular ejection fraction <30%,
restenotic lesions, lesions located in the left main coronary
artery, lesions involving a side branch >2 mm in diameter,
and the presence of thrombus or another clinically signiﬁ-
cant stenosis in the target vessel. A risk analysis of multi-
modality imaging based on previously published reports was
provided to the local ethics committees (10,11). The ethics
committees approved the protocol at the participating
institutions, and the enrolled patients gave written informed
consent before inclusion. Four patients received a non-
Absorb BVS metallic stent in addition to the study device.
Clinical endpoints were assessed at 30 days, 6 and 9 months,
and 1, 2, 3, 4, and 5 years. Noninvasive MSCT imaging
studies were planned at 5 years. All major cardiac adverse
events (MACE) were adjudicated by an independent clinicalThis study was sponsored by Abbott Vascular. Dr. Ormiston is a member of the
advisory board of Abbott Vascular. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
Manuscript received January 16, 2013; revised manuscript received May 3, 2013,
accepted May 24, 2013.
Table 1. Baseline Characteristics
Intention-to-Treat Population
(N ¼ 30)
Age, yrs 62 (54–70)
Male 18 (60)
Current smokers 6 (20)
Diabetes 1 (3)
Hypertension requiring medication 18 (60)
Hyperlipidemia requiring medication 19 (63)
Previous target vessel intervention 3 (10)
Previous myocardial infarction 1 (3)
Stable angina 21 (70)
Unstable angina 8 (27)
Silent ischemia 1 (3)
Target vessel
Left anterior descending artery 15 (47)
Left circumﬂex artery 9 (30)
Right coronary artery 7 (23)
AHA/ACC lesion classiﬁcation, %
B1 60
B2 40
Mean reference vessel diameter, mm 2.60 (2.36–3.02)
Minimal lumen diameter, mm 1.01 (0.87–.22)
Diameter stenosis, % 58 (52–70)
Lesion length, mm 8.16 (6.04–10.96)
Values are median (interquartile range) and n (%).
AHA/ACC ¼ American Heart Association/American College of Cardiology.
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1001events committee, and a data safety monitoring board
monitored patient safety.
Study device. The study device, the description of the
polymers, and in vitro and pre-clinical data have been de-
scribed elsewhere (3). The polymeric device consists of
a backbone of poly-L-lactide (PLLA) coated with poly-D,L-
lactide (PDLLA) that contains and controls the release of
the antiproliferative drug everolimus. The long chains of
PLLA and PDLLA are progressively shortened as ester
bonds between lactide repeat units are hydrolyzed. Ulti-
mately, PLLA and PDLLA fully degrade to lactic acid
that is metabolized via the Krebs cycle to H2O and CO2.
In vivo, small particles <2 mm in diameter are phagocytosed
by macrophages.
Scaffolding procedure. The Absorb BVS was implanted
after mandatory pre-dilation. When additional treatment
was required, the Cypher sirolimus-eluting stent (Cordis,
Miami, Florida) was used because there were no animal/pre-
clinical data on overlapping Absorb BVS devices available at
the time of patient enrollment. All patients were required to
receive aspirin 75 mg/day for the study duration (5 years)
and clopidogrel 75 mg/day for a minimum of 6 months.
MSCT angiography. CT scanners from all major manufac-
turers were used, including 64-slice CT (Brilliance 64,
Philips, Best, the Netherlands; CVi, GE Healthcare, Mil-
waukee, Wisconsin), 256-slice CT (iCT, Philips), 320-slice
CT (Aquilion One, Toshiba, Nasu, Japan), 64-slice dual-
source CT (Deﬁnition, Siemens AG, Forchheim, Ger-
many), and 128-slice dual-source CT (Deﬁnition Flash,
Siemens). Standard acquisition techniques were used, which
included beta-blockers in patients with a fast heart rate,
tube settings depending on patient size (80 to 140 kV),
and axial scan protocols for patients with lower heart rates
to reduce radiation doses, all at the discretion of the indi-
vidual sites. Images were reconstructed using thin slices
(0.5 to 0.67 mm) and medium smooth reconstruction ﬁlters,
including 1 or several phases depending on the scan pro-
tocol. All data were stored on a DVD for core laboratory
evaluation.
MSCT analysis. The CT data were analyzed on a dedicated
workstation (Multi-Modality Workstation, Siemens AG)
using a validated cardiovascular analysis package (Circula-
tion, Siemens AG) (12). Semiautomatically, a center lumen
line was created through the treated coronary branch after
which cross-sectional views of the vessel were reconstructed
atw1-mm longitudinal steps, including the 5 mm proximal
and distal to the device, using the platinum indicators as
landmarks. Automatic segmentation of the vessel lumen,
with manual correction was performed to measure the lumen
area. The outer vessel borders were manually traced to
approximate the total vessel size, using ﬁxed window display
settings: level, 750 Hounsﬁeld units; width, 250 Hounsﬁeld
units. The mean, minimal, and maximal lumen areas within
the treated lesion were determined for each slice. Thereference vessel lumen area was calculated as the average of
the mean proximal and mean distal vessel areas. The lumen
area stenosis was calculated as the reference minus the
minimal lumen area as a percentage of the reference lumen
area. In case of an ostial lesion or overlapping conventional
stents, the reference lumen diameter was based on mea-
surements of the opposite end only. Signiﬁcant area stenosis
was deﬁned as 75%, which approximates a 50% diameter
stenosis. Each cross section was qualitatively assessed for the
presence of noncalciﬁed plaque, calciﬁed plaque, and mixed
plaque (13–15). The percentage of cross sections of each
plaque type was calculated as a number of cross sections with
the plaque type divided by the total number of cross sections
analyzed in the scaffolded segment. The interobserver
reproducibility of minimum lumen area showed a Pearson
correlation of 0.84 with an interclass correlation coefﬁcient
for absolute difference of 0.84 (interclass correlation coefﬁ-
cient for concordance of 0.91). The mean  SD of the
difference between observers was 0.96  0.97 mm2.
MSCT-based FFR assessment. The noninvasive FFR accor-
ding to MSCT (FFRCT) was performed in a blinded fashion
by the independent core laboratory at HeartFlow, Inc.
(Redwood City, California). The detailed methodology is
described elsewhere (9). The FFRCT technology is based on
3 key principles. Because patients with rest angina were
excluded, the ﬁrst is that coronary supply meets myocardial
Figure 1. Patient Flowchart of 5-Year Follow-up
*A study device was implanted in nontarget lesion due to partial dislodgment. **At 46 days, 1 patient underwent a nonischemia-driven target lesion revascularization
and the study device was covered by a metal drug-eluting stent. FFRCT ¼ noninvasive fractional ﬂow reserve according to multislice computed tomography;
MSCT ¼ multislice computed tomography.
Onuma et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 0 , 2 0 1 3
Five-Year Follow-Up of the ABSORB Cohort A Trial O C T O B E R 2 0 1 3 : 9 9 9 – 1 0 0 9
1002demand at rest. Adherence to this principle enabled calcu-
lation of total resting coronary ﬂow relative to ventricular
mass (16,17). The second principle is that resistance of the
microcirculation at rest is inversely but not linearly propor-
tional to the size of the feeding vessel (18–23). The third
principle is that microcirculation reacts predictably to
maximal hyperemic conditions in patients with normal
coronary ﬂow (24). On the basis of these principles, a lum-
ped parameter model representing the resistance to ﬂow
during simulated hyperemia was applied to each coronary
branch of the segmented cardiac CT angiography model.
The FFRCT was modeled for conditions of adenosine-
induced hyperemia. The FFRCT core laboratory scientists
were instructed as to the location of the scaffold within
a coronary artery.
Three-dimensional models of the coronary tree and
ventricular myocardium were reconstructed with custom
methods applied to blinded cardiac CT angiography data
for simulation of coronary ﬂow and pressure. Blood was
modeled as a Newtonian ﬂuid with incompressible Navier-
Stokes equations and solved subject to appropriate initial
and boundary conditions with a ﬁnite element method
on a parallel supercomputer (25). Because coronary ﬂow
and pressure are unknown a priori, a method to couple
grouped parameter models of the microcirculation to theoutﬂow boundaries of the 3-dimensional model was used
(26–28).
Deﬁnitions. The composite clinical endpoint is cardiac
death, MI classiﬁed as Q-wave and non–Q-wave MI, and
ischemia-driven (ID) target lesion revascularization (TLR).
ID TLR implies revascularization at the target lesion, irre-
spective of the time window for angiographic control at
6 months or 2 years, associated with: 1) a positive functional
ischemia study; 2) ischemic symptoms and angiographic
minimal lumen diameter stenosis 50% by core laboratory
quantitative coronary angiography (QCA); or 3) revascu-
larization of a target lesion with a diameter stenosis 70%
by core laboratory QCA without either ischemic symptoms
or a positive functional study. For a diagnosis of non–Q-
wave MI, elevation of creatine kinase levels 2 times the
upper limit of normal with increased creatine kinase–
myocardial band was required. Scaffold thrombosis was
adjudicated according to the Academic Research Consor-
tium deﬁnitions (29). Other clinical endpoints include all-
cause mortality, non-ID TLR, and ID or non-ID target
vessel revascularization (TVR).
Statistical analysis. For binary variables, percentages were
calculated. For continuous variables, the median and inter-
quartile range were computed. For imaging assessment, truly
serial analysis is presented in tables and paired comparisons
Table 2. Hierarchical Major Adverse Cardiac Events Up to 5 Years
6 Months
(n ¼ 30)
12 Months
(n ¼ 29)*
2 Yrs
(n ¼ 29)*
5 Yrs
(n ¼ 29)*
Cardiac death 0.00 0.00 0.00 0.00
Noncardiac death 0.00 0.00 3.4 (1.0) 6.9 (2.0)
MI
Q-wave 0.00 0.00 0.00 0.00
Non–Q-wave 3.3 (1.0)y 3.4 (1.0)y 3.4 (1.0)y 3.4 (1.0)y
Cardiac death or MI 3.3 (1.0)y 3.4 (1.0)y 3.4 (1.0)y 3.4 (1.0)y
Ischemia-driven TLR
By PCI 0.00 0.00 0.00 0.00
By CABG 0.00 0.00 0.00 0.00
Ischemia-driven MACE 3.3 (1.0)* 3.4 (1.0)* 3.4 (1.0)* 3.4 (1.0)*
Nonischemia-
driven TLR
3.3 (1.0)y 3.4 (1.0)y 3.4 (1.0)y 3.4 (1.0)y
Nonischemia-
driven TVR
(non-TLR)
10.0 (3.0) 10.3 (3.0) 10.3 (3.0) 10.3 (3.0)
Any TVRz 10.0 (3.0) 10.3 (3.0) 10.3 (3.0) 10.3 (3.0)
Stroke/TIA 0.00 0.00 0.00 0.00
Values are % or % (n). *One patient withdrew consent from the study after 6 months, but the
patient’s vital status remains available through the referring physician. yThis patient also
underwent a TLR, not qualiﬁed as ischemia-driven TLR (diameter stenosis ¼ 42%) followed by
post-procedural troponin qualiﬁed as non–Q-wave MI and died of Hodgkin’s disease at 888
days post-procedure. zAny TVR includes both ischemia-driven and nonischemia-driven TVR.
CABG ¼ coronary artery bypass graft; MACE ¼ major adverse cardiac events;
MI ¼myocardial infarction; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic
attack; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 0 , 2 0 1 3 Onuma et al.
O C T O B E R 2 0 1 3 : 9 9 9 – 1 0 0 9 Five-Year Follow-Up of the ABSORB Cohort A Trial
1003between 18 months and 5 years were done by a Wilcoxon
signed rank test. The p values presented in this paper are
exploratory analyses only and should therefore be interpreted
cautiously. All statistical analyses were performed with SPSS
software version 18.0 (IBM, Armonk, New York).
Role of funding source. This study was sponsored by Abbott
Vascular. The sponsor was involved in the design and
conduct of the study and the collection, management, initial
analysis, and interpretation of the data and had the right to
a nonbinding review of the manuscript. Full monitoring
ensured accuracy of data collection. Before the end of the 5-
year follow-up, the protocol was amended to allow the
patients who had undergone an MSCT scan as an optional
investigation at 18 months to be re-consented to undergo
a second MSCT scan at 60 months.
Results
Patient demographic data and a ﬂow chart are shown in
Table 1 and Figure 1, respectively. One patient withdrew
consent from the study after the ﬁrst 6 months of follow-up
but the vital and clinical status of this patient remained
available through the referring physician. Two patients died
of a noncardiac cause during follow-up, and 5-year clinical
follow-up was obtained in the remaining 27 patients. In
29 patients with any available follow-up, the median dura-
tion of follow-up was 1,862 days.Hierarchical event rates concerning ID MACE are pre-
sented in Table 2. Up to 5 years, there was only 1 non–
Q-waveMI related to the non-IDTLRof a nonﬂow-limiting
stenosis (QCA diameter stenosis, 42%) of an Absorb at 46
days post-procedure (3,4,30,31). Two patients died of
a noncardiac cause: 1 ofHodgkin’s disease at 888 days and the
other of a duodenal perforation at 706 days. In the entire
cohort, there was no instance of scaffold thrombosis according
to either the protocol or Academic Research Consortium
deﬁnitions or a retrospective analysis requested by the U.S.
Food and Drug administration at the end of 2006 for the
assessment of on-/off-label use of the ﬁrst-generation drug-
eluting metal stents (29).
In addition to the patient described who experienced
non-ID TLR at 46 days, 2 patients experienced a non-ID
TVR. At 106 days post-procedure, in 1 patient experi-
encing angina at rest, an ergonovine test performed during
recatheterization disclosed a dynamic subtotal occlusion
(vasospasm) of the segment proximal to the scaffold; the
patient received a 3.5  22-mm paclitaxel-eluting stent
proximal to the scaffolded segment. At 5 years, the patient
presented with recurrent angina and underwent MSCT
follow-up that revealed a minimal lumen area of 2.0 mm2
but with a negative noninvasive FFRCT of 0.87, whereas
the intermediate branch had a signiﬁcant stenosis with
a positive FFRCT of 0.72 (Fig. 2). On day 1,780, invasive
angiography showed a patent scaffolded segment (%diam-
eter stenosis 35%) and a stenosed intermediate branch that
was treated with a 2.5  18-mm metallic everolimus-
eluting stent (ID TVR). The other patient who had
received an Absorb in the distal left anterior descending
artery received a metal drug-eluting stent in a moderate,
nonsigniﬁcant stenosis (QCA %DS <50%) in the left
anterior descending artery far proximal to the patent
Absorb scaffold on day 85 (30,31).
The protocol mandated a minimum of 6 months of
combined antiplatelet therapy but the actual duration was
left to the discretion of the investigators who, in general,
followed the guidelines of the European Society of Car-
diology/American College of Cardiology/American Heart
Association for antiplatelet use after metal drug-eluting stent
implantation (32,33). At 1 year, 15 patients were receiving
dual antiplatelet therapy, but only 1 patient remained on
clopidogrel therapy at 5 years (Fig. 3). This patient restarted
clopidogrel due to the repeat percutaneous coronary inter-
vention in the nontarget lesion of the intermediate branch
while the scaffolded segment was patent (Fig. 2).
Quantitative MSCT at 60 months compared with results at
18-months. At 5 years, 18 patients underwent MSCT as an
optional investigation that was performed at 3 of 4 centers
(Figs. 1 and 4). Quantitative analysis of the scaffolded
segment was feasible in all patients (Table 3). All scaffolds
were patent, with a median minimal lumen area of
3.25 mm2 (interquartile range [IQR]: 2.20 to 4.33 mm2] as
Figure 2. A Case of Non-ID TVR
The patient received an Absorb 3 12-mm scaffold in the distal left circumﬂex artery. (A) Multislice computed tomography (MSCT) post-procedure. (B) Angiography
post-procedure. (C, D) The patient received a 3.5  22-mm paclitaxel-eluting stent (visible on 18-month MSCT [yellow arrow]) proximal to the scaffolded segment as
a treatment of a pharmacologically induced vasospasm. The scaffolded segment was patent at 2-year angiographic follow-up. At 5 years, the patient presented with
recurrent angina and underwent MSCT follow-up. The maximal intensity projection of the left circumﬂex artery showed the patent scaffolded segment with inter-
mediate stenosis (between white arrows, E and F) and increased deposition of calcium (red arrows, E) in the previously implanted metal stents (yellow arrow, E).
Quantitative analysis showed a minimum lumen area of 2.0 mm2 suggesting a possibly signiﬁcant stenosis (G); however, the noninvasive fractional ﬂow reserve was
negative with a value of 0.87 (H). Angiography showed a patent scaffolded segment (%diameter stenosis 35%) and a stenosed intermediate branch (I, red arrow) that
was considered as a culprit lesion. TVR ¼ target vessel revacularization.
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1004well as 33.3% median area stenosis (IQR: 12.8% to 43.8%)
(Figs. 5 and 6). The lumen volume on average was 72.12
mm3 at 18 months and 73.85 mm3 at 60 months. At the
proximal edge, the MSCT measurement remained
numerically unchanged. In the distal segment, the vessel
area decreased signiﬁcantly from 18 months to 60 months
(D 0.70 mm2, p ¼ 0.03), which could be largely attrib-
uted to the numerical decrease in plaque area (D0.47
mm2, p ¼ 0.25) because the lumen area remained stable (D
0.01 mm2, p ¼ 1.0). In the scaffolded segment, some
similar trends in remodeling and plaque decrease were
observed, although the 4 area measurements did not
show statistically signiﬁcant change. The frequency ofnoncalciﬁed and calciﬁed plaque did not change from 18
months to 60 months.
Noninvasive FFRCT results at 60 months. Of 18 patients,
noninvasive FFR analysis was feasible in 13. In 4 patients,
severe artifact hindered FFR analysis, whereas in 1 case,
FFR could not be calculated due to incomplete documen-
tation of the entire coronary tree. The FFR distal to the
scaffolded segment was a median 0.86 (IQR: 0.82 to 0.94).
Figure 7 shows the relationship between minimal area
and noninvasive FFR distal to the scaffolded segment of the
treated vessel. The methodology also enables the practitioner
to assess the FFR continuously along each vessel of the
coronary circulation. The evaluation of the relationship was
0 365 730 1095 1460 1825
Duration (days)
Figure 3. Thienopyridine Use and Duration
The bar graph demonstrates the use and duration of thienopyridine in
individual patients.
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1005therefore also performed between minimal lumen area and
the change in FFR between the proximal and distal parts of
the scaffold landmarked by the 2 radiopaque markers
(Fig. 7). There were 3 asymptomatic patients with an
FFRCT between 0.75 and 0.80.Discussion
This report on 5-year clinical outcomes of the ﬁrst-in-
humans ABSORB trial demonstrates a low ID MACE rate
of 3.4% (1 patient) without any scaffold thrombosis, early,
late, or very late. The serial noninvasive quantitative MSCT
assessment was feasible with an option of functionality
assessment and demonstrated that the lumen and vessel
dimensions were unchanged from 18 months to 5 years.
According to the protocol, 5-year follow-up is the last
follow-up of this ﬁrst-in-humans study conducted for the
phase II trial of the everolimus-eluting bioresorbable scaf-
fold. Instead of performing invasive follow-up, noninvasive
follow-up with MSCT was optionally performed at 3 of
4 centers for the following reasons: at the time of writing the
protocol in 2005, it already appeared challenging to plan 2
angiographic follow-ups at 6 and 24 months for purely
scientiﬁc reasons, and 5-year invasive follow-up was not
planned. The invasive imaging of IVUS and OCT at 2 years
demonstrated the beneﬁcial effects of the device such as late
lumen enlargement with restoration of vasoreactivity, which
renders difﬁcult the justiﬁcation of an additional invasive
follow-up at 5 years. In addition, the 2-year QCA was
actually limited in 19 of 30 patients because 11 patients
either withdrew their consent or refused the repeat invasive
imaging at 2 years, whereas MSCT at 18 months was
available for 25 patients (4). We therefore decided not toperform invasive imaging of IVUS and OCT but rather to
repeat MSCT imaging that could be performed non-
invasively and could provide enough information on the
evolution of the wall thickness and lumen from 18 months
to 60 months.
The trial conﬁrmed the feasibility of noninvasive func-
tional and anatomic assessment of the scaffold, a fact that
opens new avenues for noninvasive control of the patency of
treated coronary lesions. Currently some manufacturers have
increased the radiopacity of their metal struts by using a new
radiopaque alloy such as platinum, facilitating the acute
positioning and deployment of the device but rendering
the assessment of the patency by noninvasive MSCT
problematic (1,34).
The serial assessment of the lumen by MSCT revealed the
persistence of the lumen area up to 5 years after the ever-
olimus-eluting bioresorbable scaffold implantation with
a nonsigniﬁcant decrease in plaque area, which could be the
result of dissolution and incorporation of the polylactide
struts into the vessel wall. Pre-clinical data showed a
completion of polylactide mass loss (i.e., bioresorption) of
70% and 100% at 18 months and at 2 years, respectively.
However, OCT can still image the strut as a black box at
2 years, but on histology, the polylactide polymeric strut has
already been bioresorbed and is replaced by proteoglycan. At
3 and 4 years, the strut void has been ﬁlled in with the
connective tissue replacing proteoglycan, which results in
shrinkage of strut void on histology. The decrease in plaque
area observed in the current analysis may therefore reﬂect
this integration process after bioresorption between 2 and
5 years, although the resolution of the MSCT technique
and the small number of observation do not allow statistical
signiﬁcance to be reached.
Coronary atherosclerosis is a continuous disease process
and necessitates preventive measures and intensive phar-
macological treatment. Indeed, after bioresorption of the
polymer, the vessel and the lumen are able to change
dynamically in response to physiological stimuli, biological
environment, and pharmacological treatment due to the
absence of a permanent metal endoluminal prosthesis (35).
This emphasizes the importance of treating the underlying
atherosclerotic process after a bioresorbable scaffold im-
plantation. It should be underscored that in the absence of
a metal structure, restenosis after scaffolding can be treated
with another scaffold without any of the complexities of
treating classic in-stent restenosis within a metal stent. In
the near future, scaffolding, in theory, could be applied after
appropriate preparation of the stenotic lesion using the
classic tools of the interventional cardiologist such as rota-
blators, cutting balloons, laser, high-pressure balloons, and
others.
The FFRCT has been validated against invasive FFR in
2 multicenter trials, demonstrating that the technology has
a good correlation with an invasive FFR and adds more
Figure 4. A Case Example of 5 Year MSCT Follow-up
The patient had a short stenotic lesion in the proximal right coronary artery (A) that was successfully treated by a 3  12-mm Absorb Bioresorbable scaffold (white
arrows in B). At 6 months (C) and 2 years (D), angiographic follow-up was performed to demonstrate the patent scaffolded segment (white arrows). At 5 years,
multislice computed tomography (MSCT) follow-up was performed and demonstrated a patent scaffolded segment (red rectangle in volume rendering image in E). In
maximal intensity projection (F), the metal markers indicating both ends of the scaffold remained visible as white dots on MSCT 5 years after implantation. MSCT was
further processed for assessment of noninvasive fractional ﬂow reserve (FFR), which demonstrated the absence of functionally signiﬁcant stenosis in the proximal and
distal segments of the scaffolded segment (G, 0.96 and 0.94, respectively). The noninvasive FFR also proved the absence of any signiﬁcant stenosis in all major
epicardial vessels (H, distal right coronary artery, 0.86; distal left anterior descending artery, 0.92; distal left circumﬂex artery, 0.93).
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1006accuracy on diagnosis of coronary artery disease compared
with quantitative MSCT (9,36). In the current study, the
feasibility of quantitative assessment of coronary MSCT was
100%, whereas the noninvasive FFR assessment was possible
in 72%. Good image quality of all coronary arteries and low
heart rate are mandatory for noninvasive FFR because the 3-
dimensional modeling of the entire coronary tree is indis-
pensable for ﬂow simulation. For quantitative assessment of
the lumen, the image quality of the nonscaffolded segment is
technically less demanding because the imaging protocol
only focused on the scaffold area. Due to the post-hoc
assessment of MSCT acquisition, no speciﬁc investigational
requirement such as a low heart rate was prospectivelyrecommended to the investigators. The feasibility of FFRCT
could, in the near future, be improved as the image is
acquired optimally and the imaging technology further
advanced.
The computational algorithms used in the FFRCT anal-
ysis provide highly reproducible results well within the
precision of measured FFR. Of note, published reports
demonstrate that FFRCT accuracy is less affected by MSCT
image quality than CT stenosis (37). Regarding the short-
(5 min) or medium- (1 h) term reproducibility, radiation and
patient safety concerns have precluded repeat MSCT studies
on the same patient to investigate such reproducibility
of the image data acquisition as historically assessed for
Table 3. Serial Quantitative MSCT Assessment at 18 Months and 5 Years
18 Months 5 Yrs
Difference
(5 Yrs  18 Months) p Value
Proximal segment, mm2 (n ¼ 15)
Minimal lumen area 4.70 (3.30 to 5.30) 4.80 (3.10 to 6.20) 0.10 (0.50 to 1.40) 0.31
Mean lumen area 5.82 (3.78 to 6.52) 5.85 (4.12 to 7.50) 0.10 (0.58 to 0.78) 0.60
Mean vessel area 12.80 (10.80 to 18.00) 12.70 (11.60 to 15.00) 0.40 (2.60 to 2.00) 1.0
Mean plaque area 7.02 (6.58 to 10.62) 6.85 (6.00 to 9.13) 0.10 (1.84 to 1.68) 0.93
Distal segment, mm2 (n ¼ 16)
Minimal lumen area 4.15 (2.35 to 5.00) 3.45 (2.65 to 4.90) 0.10 (0.80 to 1.10) 0.92
Mean lumen area 4.97 (3.22 to 5.69) 4.56 (3.08 to 5.96) 0.01 (0.68 to 0.90) 1.0
Mean vessel area 11.90 (8.80 to 15.40) 11.40 (8.30 to 13.60) 0.70 (1.70 to 0.00) 0.03
Mean plaque area 7.49 (5.60 to 9.75) 5.79 (4.69 to 8.33) 0.47 (2.07 to 0.48) 0.25
Scaffolded segment, mm2 (n ¼ 18)
Minimal lumen area 3.10 (2.10 to 3.80) 3.25 (2.20 to 4.30) 0.20 (0.20 to 0.90) 0.21
Mean lumen area 4.47 (3.36 to 5.58) 4.29 (3.38 to 5.73) 0.36 (0.08 to 0.62) 0.11
Mean vessel area 13.17 (10.35 to 15.93) 11.93 (9.00 to 16.47) 0.31 (1.63 to 0.54) 0.26
Mean plaque area 8.23 (6.98 to 11.18) 7.10 (5.44 to 10.14) 1.31 (2.23 to 0.81) 0.23
Mean reference area 5.23 (3.62 to 6.08) 5.29 (3.47 to 6.30) 0.08 (0.45 to 0.80) 0.76
Area stenosis, % 31.6 (25.6 to 45.8) 33.3 (13.2 to 40.7) 2.3 (10.8 to 2.0) 0.25
Cross sections with noncalciﬁed plaque, % 100 (52.9 to 100.0) 87.5 (33.3 to 100.0) 0.0 (8.9 to 0.0) 0.12
Cross sections with mixed plaque, % 0 (0 to 43.8) 6.25 (0 to 56.3) 0.0 (0.0 to 4.8) 0.37
Cross sections with calciﬁed plaque, % 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0.50
FFRCT (n ¼ 13)
Proximal 0.91 (0.88 to 0.96)
Distal 0.86 (0.82 to 0.94)
D (distal FFRCT  proximal FFRCT) 0.03 (0.05 to 0.02)
Values are median (interquartile range).
FFRCT ¼ noninvasive fractional ﬂow reserve according to multislice computed tomography; MSCT ¼ multislice computed tomography.
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1007quantitative coronary angiography (38). Patient preparation,
contrast timing, and scan technique would be expected to
affect the quality and reproducibility of the resultant images.Figure 5. Cumulative Frequency Distribution Curves of Mean Lumen
Area, Plaque Area, and Vessel Area at 18 Months and 5 Years
All frequency distribution curves as assessed by multislice computed
tomography.Study limitations. This ﬁrst-in-humans trial included only
patients with a single and simple anatomic lesion in a pop-
ulation in which a majority of patients presented withFigure 6. MLA Versus Area Stenosis in the Scaffolded Segment (n ¼ 18)
The median of minimal lumen area and area stenosis was 3.25 mm2 (IQR: 2.20
to 4.30) and 33.3% (IQR: 12.8 to 43.8), respectively. The dashed lines
indicate 75% area stenosis and 25% of nominal area. Nominal area is the
theoretical area of a scaffold of 3.0 mm (e.g., 7.07 mm2). AS ¼ area stenosis;
IQR ¼ interquartile range; MLA ¼ minimal lumen area.
Figure 7. Minimum Lumen Area Versus Noninvasive FFR
(Left) A scatterplot of 5-year noninvasive FFRCT immediately distal to the scaffold versus quantitative MLA in the scaffold segment assessed by multislice computed
tomography (MSCT) (n ¼ 13). (Right) A scatterplot of the change in FFRCT across the scaffolded segment (distal FFRCT  proximal FFRCT) versus MLA. There were 3
asymptomatic patients with a FFRCT value between 0.75 and 0.80. In 2 patients, MSCT revealed an intermediate stenosis at least 5 mm proximal to the scaffolded
segment, whereas the scaffolded segments showed no ﬂow-limiting stenoses with a minimal FFRCT gradient of 0.01 and 0.02 (right, yellow and orange dots). The
third patient (red dot) had diffuse disease with a FFRCT of 0.71 in the distal segment of the left anterior descending artery. According to the investigational protocol of
this center, the patient underwent a diagnostic angiography by catheterization, during which an invasive FFR showed a progressive, nonlocalized pressure gradient in
the diffusely diseased left anterior descending artery. Due to the absence of focal ﬂow-limiting stenosis, the asymptomatic patient was kept under medical treatment.
FFR ¼ fractional ﬂow reserve; FFRCT ¼ noninvasive fractional ﬂow reserve according to multislice computed tomography; MLA ¼ minimal lumen area.
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1008stable angina. Although the standard MSCT acquisition
techniques were used, the scan protocol was adjusted for
different MSCT scanners used at each institution and each
follow-up at the discretion of individual sites. To control the
acquisition quality, however, the sites were asked twice, at
18 and 60 months, to send test run MSCT data to the
MSCT core laboratory for review of protocol compliance
and data quality. The small numbers of patients followed by
noninvasive angiography is more related to the optional
character of the investigation than to the lack of technical
feasibility. So far, the clinical validation of this new meth-
odological approach has only been obtained in 1 clinical trial
and awaits further validation.
Conclusions
The low event rate at 5 years suggests sustained safety after
the implantation of a fully bioresorbable Absorb everolimus-
eluting scaffold. Noninvasive assessment of the coronary
artery after treatment with this device is feasible, with the
possibility of simultaneous functional assessment in selected
cases.Acknowledgments
The authors thank Dr. Akira Kurata for his intellectual input.
They also thank Cecile Dorange, Karine Miquel-Hebert,
Susan Veldhof, Chuck Simonton, and Krishnankutty Sudhir
for their intellectual input in reviewing the manuscript.
Reprint requests and correspondence: Dr. Patrick W. Serruys,
Thoraxcenter Erasmus Medical Center, Gravendijkwal 230, 3015
CE Rotterdam, the Netherlands. E-mail: p.w.j.c.serruys@
erasmusmc.nl.REFERENCES
1. Otsuka M, Tanimoto S, Sianos G, et al. “Radio-lucent” and “radio-
opaque” coronary stents characterized by multislice computed tomog-
raphy. Int J Cardiol 2009;132:e8–10.
2. Eggebrecht H, Rodermann J, Hunold P, et al. Images in cardiovascular
medicine. Novel magnetic resonance-compatible coronary stent: the
absorbable magnesium-alloy stent. Circulation 2005;112:e303–4.
3. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-
eluting coronary stent system for patients with single de-novo coronary
artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;
371:899–907.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 0 , 2 0 1 3 Onuma et al.
O C T O B E R 2 0 1 3 : 9 9 9 – 1 0 0 9 Five-Year Follow-Up of the ABSORB Cohort A Trial
10094. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable ever-
olimus-eluting coronary stent system (ABSORB): 2-year outcomes and
results from multiple imaging methods. Lancet 2009;373:897–910.
5. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute
stent recoil between the bioabsorbable everolimus-eluting coronary stent
and the everolimus-eluting cobalt chromium coronary stent: insights
from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv
2007;70:515–23.
6. Tanimoto S, Bruining N, van Domburg RT, et al. Late stent recoil of
the bioabsorbable everolimus-eluting coronary stent and its relationship
with plaque morphology. J Am Coll Cardiol 2008;52:1616–20.
7. García-García HM, Gonzalo N, Pawar R, et al. Assessment of the
absorption process following bioabsorbable everolimus-eluting stent
implantation: temporal changes in strain values and tissue composition
using intravascular ultrasound radiofrequency data analysis. A substudy
of the ABSORB clinical trial. EuroIntervention 2008;4:443–8.
8. Voros S, Rinehart S, Qian Z, et al. Prospective validation of stan-
dardized, 3-dimensional, quantitative coronary computed tomographic
plaque measurements using radiofrequency backscatter intravascular
ultrasound as reference standard in intermediate coronary arterial
lesions: results from the ATLANTA (assessment of tissue characteris-
tics, lesion morphology, and hemodynamics by angiography with frac-
tional ﬂow reserve, intravascular ultrasound and virtual histology, and
noninvasive computed tomography in atherosclerotic plaques) I study.
J Am Coll Cardiol Intv 2011;4:198–208.
9. Koo BK, Erglis A, Doh JH, et al. Diagnosis of ischemia-causing
coronary stenoses by noninvasive fractional ﬂow reserve computed from
coronary computed tomographic angiograms. Results from the
prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-
Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve)
study. J Am Coll Cardiol 2011;58:1989–97.
10. Jang IK, Bouma BE, Kang DH, et al. Visualization of coronary
atherosclerotic plaques in patients using optical coherence tomography:
comparison with intravascular ultrasound. J Am Coll Cardiol 2002;39:
604–9.
11. Nissen SE, Gurley JC, Grines CL, et al. Intravascular ultrasound
assessment of lumen size and wall morphology in normal subjects and
patients with coronary artery disease. Circulation 1991;84:1087–99.
12. Leber AW, Johnson T, Becker A, et al. Diagnostic accuracy of dual-
source multi-slice CT-coronary angiography in patients with an inter-
mediate pretest likelihood for coronary artery disease. Eur Heart J 2007;
28:2354–60.
13. Voros S, Rinehart S, Qian Z, et al. Coronary atherosclerosis imaging by
coronary CT angiography: current status, correlation with intravascular
interrogation and meta-analysis. J Am Coll Cardiol Img 2011;4:
537–48.
14. Raff GL, Abidov A, Achenbach S, et al. SCCT guidelines for the
interpretation and reporting of coronary computed tomographic angi-
ography. J Cardiovasc Comput Tomogr 2009;3:122–36.
15. Lehman SJ, Schlett CL, Bamberg F, et al. Assessment of coronary
plaque progression in coronary computed tomography angiography
using a semiquantitative score. J Am Coll Cardiol Img 2009;2:1262–70.
16. West GB, Brown JH, Enquist BJ. A general model for the origin of
allometric scaling laws in biology. Science 1997;276:122–6.
17. Steele BN, Olufsen MS, Taylor CA. Fractal network model for simu-
lating abdominal and lower extremity blood ﬂow during resting and
exercise conditions. Comput Methods Biomech Biomed Eng 2007;10:
39–51.
18. Murray CD. The physiological principle of minimum work: I. The
vascular system and the cost of blood volume. Proc Natl Acad Sci U S A
1926;12:207–14.
19. Hutchins GM, Miner MM, Boitnott JK. Vessel caliber and branch-
angle of human coronary artery branch-points. Circ Res 1976;38:572–6.
20. Kamiya A, Togawa T. Adaptive regulation of wall shear stress to ﬂow
change in the canine carotid artery. Am J Physiol 1980;239:H14–21.
21. Zarins CK, Zatina MA, Giddens DP, Ku DN, Glagov S. Shear stress
regulation of artery lumen diameter in experimental atherogenesis.
J Vasc Surg 1987;5:413–20.22. Zhou Y, Kassab GS, Molloi S. On the design of the coronary
arterial tree: a generalization of Murray’s law. Phys Med Biol 1999;
44:2929–45.
23. Zhou Y, Kassab GS, Molloi S. In vivo validation of the design rules of
the coronary arteries and their application in the assessment of diffuse
disease. Phys Med Biol 2002;47:977–93.
24. Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD.
Effects of adenosine on human coronary arterial circulation. Circulation
1990;82:1595–606.
25. Kim HJ, Vignon-Clementel IE, Figueroa CA, Jansen KE, Taylor CA.
Developing computational methods for three-dimensional ﬁnite
element simulations of coronary blood ﬂow. Finite Elements Anal
Design 2010;46:514–25.
26. Müller J, Sahni O, Li X, Jansen KE, Shephard MS, Taylor CA.
Anisotropic adaptive ﬁnite element method for modelling blood ﬂow.
Comput Methods Biomech Biomed Engin 2005;8:295–305.
27. Sahni O, Müller J, Jansen KE, Shephard MS, Taylor CA. Efﬁcient
anisotropic adaptive discretization of the cardiovascular system. Comput
Methods Appl Mech Engrg; 2006:5634–55.
28. Kim HJ, Vignon-Clementel IE, Coogan JS, Figueroa CA, Jansen KE,
Taylor CA. Patient-speciﬁc modeling of blood ﬂow and pressure in
human coronary arteries. Ann Biomed Eng 2010;38:3195–209.
29. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in
coronary stent trials: a case for standardized deﬁnitions. Circulation
2007;115:2344–51.
30. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K,
Serruys PW. Four-year clinical follow-up of the ABSORB ever-
olimus-eluting bioresorbable vascular scaffold in patients with de novo
coronary artery disease: the ABSORB trial. EuroIntervention 2012;7:
1060–1.
31. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of
clinical follow-up after a bioresorbable everolimus-eluting scaffold in
patients with de novo coronary artery disease: the ABSORB trial.
EuroIntervention 2010;6:447–53.
32. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous
coronary interventions. The Task Force for Percutaneous Coronary
Interventions of the European Society of Cardiology. Eur Heart J 2005;
26:804–47.
33. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI
2005 guideline update for percutaneous coronary intervention: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing
Committee to Update the 2001 Guidelines for Percutaneous Coronary
Intervention). J Am Coll Cardiol 2006;47:e1–121.
34. Hamon M, Champ-Rigot L, Morello R, Riddell JW. Diagnostic
accuracy of in-stent coronary restenosis detection with multislice
spiral computed tomography: a meta-analysis. Eur Radiol 2008;18:
217–25.
35. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to
transient bioresorbable scaffolds: change in paradigm of coronary
revascularization in the upcoming decade? Eur Heart J 2012;33:16–25b.
36. Min JK, Leipsic J, Pencina MJ, et al. Diagnostic accuracy of frac-
tional ﬂow reserve from anatomic CT angiography. JAMA 2012;308:
1237–45.
37. Min JK, Koo BK, Erglis A, et al. Effect of image quality on diagnostic
accuracy of noninvasive fractional ﬂow reserve: results from the
prospective multicenter international DISCOVER-FLOW study.
J Cardiovasc Comput Tomogr 2012;6:191–9.
38. Reiber JH, Serruys PW, Kooijman CJ, et al. Assessment of short-,
medium-, and long-term variations in arterial dimensions from
computer-assisted quantitation of coronary cineangiograms. Circulation
1985;71:280–8.Key Words: bioresorbable scaffold - everolimus -
multislice computed tomography - noninvasive functional
assessment.
